Soligenix (SNGX) Cash from Investing Activities (2010 - 2025)

Soligenix's (SNGX) quarterly Cash from Investing Activities came in at -$1962.0 in Q4 2025, down 222.7% on a QoQ basis from -$608.0 in Q3 2025.

Soligenix (SNGX) Cash from Investing Activities (2010 - 2025) Analysis & Trends

Soligenix (SNGX) has 13 years of Cash from Investing Activities data on file, last reported at -$1962.0 in Q4 2025.

Quarterly Cash from Investing Activities changed N/A year-over-year to -$1962.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2570.0 (changed N/A YoY) and the FY2025 annual result came in at -$5883.0, changed N/A from the prior year.
Cash from Investing Activities eased to -$1962.0 in Q4 2025, from -$608.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of -$608.0 in Q3 2025 to a low of -$9823.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-45.80 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-92.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	329.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-49.35 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-363.46 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-3.17 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	24.51 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-229.72 Mn
10	Soligenix	6.45 Mn	6.45 Mn	-	-

Download Data